Press coverage about Celgene (NASDAQ:CELG) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celgene earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9732319668213 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Campbell Soup, Celgene Stumble into Friday’s 52-Week Low Club (247wallst.com)
- Call buyers look for Celgene to turn around (nasdaq.com)
- Trump attacks Celgene business record that Menendez Republican foe Hugin touts (nj.com)
- Celgene (CELG) CEO Mark J. Alles Purchases 1,208 Shares (americanbankingnews.com)
- The Punching Bag of Biotech Absorbs More Blows (bloomberg.com)
Several equities research analysts have recently weighed in on the company. BMO Capital Markets reissued a “buy” rating and set a $144.00 price objective on shares of Celgene in a research note on Wednesday, January 24th. SunTrust Banks reissued a “buy” rating and set a $139.00 price objective (up from $127.00) on shares of Celgene in a research note on Friday, January 26th. Cantor Fitzgerald reissued a “hold” rating and set a $112.00 price objective on shares of Celgene in a research note on Monday, January 29th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective for the company in a research note on Thursday, January 25th. Finally, Royal Bank of Canada reissued a “top pick” rating on shares of Celgene in a research note on Tuesday, January 23rd. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average price target of $123.98.
CELG traded down $1.61 during trading on Friday, reaching $78.37. 7,749,278 shares of the stock traded hands, compared to its average volume of 6,738,399. The stock has a market cap of $56.80 billion, a price-to-earnings ratio of 11.46, a PEG ratio of 0.52 and a beta of 1.49. Celgene has a fifty-two week low of $78.35 and a fifty-two week high of $147.17. The company has a current ratio of 2.53, a quick ratio of 2.36 and a debt-to-equity ratio of 3.92.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.09. Celgene had a return on equity of 72.92% and a net margin of 20.73%. The firm had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.47 billion. During the same quarter last year, the firm earned $1.68 earnings per share. The business’s revenue for the quarter was up 19.4% on a year-over-year basis. sell-side analysts forecast that Celgene will post 7.63 earnings per share for the current fiscal year.
Celgene declared that its board has authorized a stock buyback plan on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.
In related news, CEO Mark J. Alles bought 1,208 shares of the business’s stock in a transaction on Wednesday, May 9th. The shares were bought at an average cost of $82.60 per share, for a total transaction of $99,780.80. Following the completion of the acquisition, the chief executive officer now directly owns 187,316 shares in the company, valued at $15,472,301.60. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total value of $877,177.50. Following the transaction, the director now owns 94,801 shares in the company, valued at $8,989,978.83. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,870 shares of company stock worth $2,991,601. Corporate insiders own 0.95% of the company’s stock.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.